Risk factors for melanoma among survivors of non-Hodgkin lymphoma
the ONA take:
Investigators sought to quantify risks associated with specific treatments and immune-related risk factors for cutaneous melanoma among survivors of non-Hodgkin lymphoma.
This research follows previous studies that reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of developing cutaneous melanoma.
Risk of second melanoma was evaluated in 44,870 1-year survivors of first primary NHL. A total of 202 second melanoma cases were identified among the survivors, including 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes.
This research revealed a significantly increased risk of melanoma among survivors of CLL/SLL who received infused fludarabine-containing chemotherapy with or without rituximab. Risk of melanoma was not associated with specific treatments among survivors of other subtypes of NHL.
The investigators conclude that immune perturbation may contribute to risk of melanoma after CLL/SLL. Survivors of NHL should be vigilantly followed to ensure early detection of melanoma.
Survivors of non-Hodgkin lymphoma have an increased risk of developing cutaneous melanoma.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|